GlassScriptPhysician profile
Jacqueline L Michael
NPI 1841466158
$8,223.28
in general payments reported to CMS, 2019-2025
34 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $454 · 2022: $2,336 · 2023: $2,346 · 2024: $1,515 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,184 · Honoraria: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,183.60 |
| Honoraria | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,280.72 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $912.70 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $861.29 | 2023-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $717.99 | 2021-2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $662.19 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $559.89 | 2022-2025 | |
| Genzyme Corporation | $401.42 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $385.85 | 2022-2025 | Ingrezza |
| Alnylam Pharmaceuticals INC. | $215.57 | 2021-2025 | Amvuttra |
| Ironshore Pharmaceuticals INC. | $190.53 | 2022-2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.96 | 2022-2023 | Xifaxan |
| Novo Nordisk INC | $172.96 | 2022 | |
| Corium, LLC | $169.31 | 2022-2023 | Azstarys |
| Alkermes, INC. | $148.92 | 2024 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.34 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.12 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $120.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.17 | 2022 | |
| Exeltis, USA INC. | $103.35 | 2025 | Slynd, Twirla |
| Jazz Pharmaceuticals INC. | $100.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $94.69 | 2022 | |
| Stemline Therapeutics INC. | $83.07 | 2022 | |
| Dexcom, INC. | $79.31 | 2022 | |
| Medtronic, INC. | $71.43 | 2022 | |
| Horizon Therapeutics Plc | $69.98 | 2022 | |
| Lundbeck LLC | $46.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.77 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.29 | 2022 | |
| Tris Pharma INC | $16.15 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $15.86 | 2022 | |
| Merck Sharp & Dohme LLC | $14.76 | 2022 | |
| Adlon Therapeutics L.P. | $12.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.